Changes to BoD in Lytix Biopharma as part of preparations for the IPO
Lytix Biopharma announces, after yesterday’s Extraordinary General Assembly, that there are changes in the company’s BoD. According to Norwegian government law it is required to have a more equal gender split in the board of listed companies (ASA) than what Lytix Biopharma had, so the changes are part of the preparations for Lytix Biopharma to become a listed company.
As of today, the new Board of Directors in Lytix Biopharma consists of:
· Gert W. Munthe (Chairman)
· Kari Grønås
· Morten Jurs
· Lena Torlegård
· Debasish Roychowdhury
Gert Wilhelm Munthe, the Chairman of Lytix Biopharma, thanks the previous board members, Knut Eidissen and John Sigurd Svendsen, and says:
“On behalf of the Board, I would like to thank Knut and John Sigurd for all their efforts and achievements for Lytix through several years. They both have contributed in an excellent way. Their roles in the board have been essential, and they will still play an active role in the company through being a main shareholder and managing our patent portfolio, respectively.”
Knut Eidissen, previous member of the board of directors in Lytix Biopharma, says:
"Lytix Biopharma is now at a very important stage of the company. After 7 years as chairman followed by 2 years as a board member, I´m now leaving the board. It has both been exciting and hard work to build Lytix Biopharma. I have met a lot of positive and knowledgeable people and wish to thank all those who have contributed to the progress of Lytix Biopharma. This gratitude also extends to our shareholders, employees, The Research Council of Norway and Innovation Norway. I will continue to follow the company closely, and I trust the remaining board members will lead Lytix Biopharma through the important milestones and create value for Lytix Biopharma's shareholders."